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Traditional development of novel therapeutics assesses product risks and benefits in Phase 
III trials. When questions remain, licensing may be deferred whilst clarification is sought. To 
help deliver new medicines to patients sooner, Post Authorisation Safety Studies (PASS) 
and Post Authorisation Efficacy Studies (PAES) have been introduced by medicines 
regulators.  Regulators recognise the efficiencies of registries to deliver these studies and 
the use of established patient registries is encouraged by the European Medicines Agency 
(EMA)(1).   
 
Patient or disease registries are typically developed by the clinical community. Whilst not 
usually designed for post authorisation safety/effectiveness evaluation, they may be adapted 
for this purpose and have the benefit of providing longer term understanding of a specific 
disease (2). Treatment registries developed by pharmaceutical companies usually provide 
specific post authorisation data limited to the timeframe of the request. 
 
Cystic Fibrosis is found in 1 in 2200 people in the UK with 90% now detected by newborn 
screening enabling detailed monitoring from birth. Median life expectancy is currently 47 
years of age. The UK Cystic Fibrosis Registry (UKCFR) , with records of over 10000 
patients, is sponsored by the UK Cystic Fibrosis Trust. With appropriate authorisations and 
consent, data representing 99% of the UK CF population are entered by care teams in all UK 
CF Centres. (5) Data is collected from multiple disease domains (demographics, diagnosis, 
complications, mortality, laboratory data, nutrition, pulmonary function, respiratory 
microbiology, physiotherapy) with a summary reported annually (6).In 2015 the UKCFR 
passed an audit against Good Pharmacoepidemiology Practice standards. 
We report a model for successful partnership with industry in the conduct of post 
authorisation studies, utilising a rare disease patient registry.  Our five year experience 
demonstrates the potential for improving the quality of pharmacovigilance by utilising the 
unique strength of a registry study - the ability to compare exposed and unexposed patients 
in cohorts matched for key characteristics. In this paper we examine the key components of 
the model. 
Our pharmacovigilance programme began in 2012 and was initiated by EMA requests to 
three companies, to develop long term safety studies for cystic fibrosis products.  In the 
same year, the EMA produced guidelines and templates for PASS protocols and final reports 
(3) and in 2015 for PAES (4). Key opportunities which influenced the decision to support this 
initiative was the potential for improving the methodology of long term safety studies and for 
engaging and encouraging industry involvement in cystic fibrosis therapeutics.  
The principal components of the CF Trust Pharmacovigilance Model are: 
 
 A UK Lead Investigator, who is an appropriate CF physician, provides independent 
clinical guidance and Registry expertise to industry partners and the EMA in the 
development of the study protocol, and contributes to the interim and final reports.   
 
 Senior Statisticians, independent of the marketing authorisation holder (MAH), contribute 
to the development of the study protocol and statistical analysis plan, conduct analyses 
and draft reports. EMA designated formats are adopted for reporting of summary 
anonymised data (7). 
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 Pharmacovigilance programme support, to construct delivery plans for interim and final 
reports, and agree timelines, through drafting to final version (approximately 2-3 
months). The MAH submits reports to the EMA, sharing feedback with the UKCFR to 
enable changes to the analysis for subsequent reports.  
 
The Trust has worked with professional NHS R&D and legal advisers to develop a standard 
Services Agreement between the Trust and the MAH.  The main provisions of the 
Agreement are in Panel 1.  
 
    Panel 1:Study Services Agreement Provisions 
 
Engagement:  Clear exposition of the services to be provided,    
    in accordance with the Study Protocol 
 
Study Governance:  Parties comply with all applicable laws, statutes    
    and guidance of EU and UK  
 
Confidentiality:  Non-disclosure of personal data and patient-level data in study reports 
    Company and Cystic Fibrosis Trust business confidentiality 
 
Intellectual Property: The Trust grants a licence to the Company for access to anonymised 
data analysis and resulting reports only 
 
     Stated Use   Summary data reports to be used only for the agreed and stated 
purpose of a PASS/PAES 
 
Publication:   Provisions to ensure that results of scientific interest are published in 
the public domain 
 
Funding: The financial agreement between the Trust and the MAH ensures 
that the company covers all the costs of conducting the study and 
that none of the work is subsidised by either the Charity or the NHS.  
Each company pays a set-up fee to cover the costs incurred by the 
Trust in adding any new variables to the UKCFR, and the preparatory 
work needed to agree the study protocol and the service agreement.  
The services funded during the length of the study include a 
contribution to the costs of data collection within CF Centres, 
provided in the form of grants from the Trust, and the full costs of 
project management, analysis and reporting 
 
 
Funding to support the pharmacovigilance programme has driven improvements in the 
Registry and enabled a financial contribution to be made to UK CF Centres to facilitate data 
entry.  The resulting enhancements to the UKCFR, particularly in medication dates and 
patient outcomes, have been of benefit to other researchers using the Registry, and to the 
NHS in monitoring the impact of new drugs. 
 
The most important element in study design is the ability to capture information on all users 
of the medicine in a real world situation, which can include “off label” use and those patients 
with mild or severe disease who are often excluded in the randomised control trial (RCT) 
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setting. Adverse effects of new compounds highlighted in RCTs may readily be targeted for 
enhanced surveillance but a disease registry provides the ability to capture a broader range 
of events over several years of exposure. The ability to compare exposed and unexposed 
patients in cohorts matched for key characteristics is a significant strength of patient 
registries, and pre-defined comparator groups (usually selected using a propensity scoring 
system) allow longitudinal tracking of outcomes. Studies should commence at point of 
medicine authorisation to have optimal opportunity to capture safety/effectiveness in the 
population.  
In Figure 1 is an example of a study flowchart, beginning with the whole UKCFR patient 
population, through the stages of selection of the study groups and a typical matching 
process to end up with the final groups for analysis. 
 
Figure 1 Study Cohorts Flowchart 
 
 
 
A summary of the current studies in the programme is provided in Table1. The Observational 
Study to Evaluate the Long-Term Safety of Ivacaftor in Patients with Cystic Fibrosis, 
commenced in the UK in 2013, has reported interim results (8).  
 
 
 
 
Total 
Population
N=10000
Exposed
n=1500
Matched by PS 
only n =200
Matched by PS 
and Date of 
Annual Review
n= 1250
Matched 
Exposed
n=1450
No Propensity 
Score (PS) =50
Unexposed
n=5000
Matched by PS  
only n=500
Matched by PS  
and Date of 
Annual Review
n= 2300
Matched 
Unexposed
n=2800
No PS = 200
Not Matched = 2000
Not in exposed or 
comparator 
groups =3500
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Table 1 
 
 
MAH Pharmaxis Ltd Vertex 
Pharmaceuticals 
(UK) Limited 
Forest/Teva Vertex 
Pharmaceuticals 
(Europe) Limited 
Chiesi 
Pharmaceuticals 
Medicinal 
Product 
Bronchitol™ Kalydeco® Colobreathe® Kalydeco® Quinsair® 240 
mg nebuliser 
solution 
Timeline 
 
2012-2017 2013-2017 2014-2019 2016-2022 2017-2021 
Study 
 
PASS PASS PASS PAES PASS 
EU PAS 
Reg. No. 
20668 4270 16395  20990 
Design Observational 
comparative 
cohort study 
Observational 
comparative 
cohort study 
Observational 
comparative 
cohort study 
Observational 
comparative 
cohort study 
Observational 
comparative 
cohort study 
Exposed  
Group 
 Adult (≥ 18yrs) 
Bronchitoltreated 
patients   
Ivacaftor treated 
patients (≥ 6 yrs) 
Colobreathe 
treated patients 
Kalydeco 
treated patients 
aged 2-5 yrs at 
therapy initiation 
Quinsair treated 
patients 
Comparison 
Groups 
a) Matched Non-
Bronchitol 
treated patients 
b)Full 
unexposed 
population  
Patients with no 
evidence of 
Ivacaftor 
exposure 
Patients treated 
with other 
inhaled anti-
pseudomonal 
antibiotics. 
Patients with no 
evidence of 
Ivacaftor 
exposure 
Patients treated 
with other 
inhaled approved 
antibiotic 
therapies  
Matching Propensity score 
and date of 
annual review 
CFTR genotype 
class, age and 
gender 
Propensity 
score and date 
of annual review 
CFTR genotype 
class, nutritional 
status, age and 
gender 
 
 
In the development of registry- based post authorisation studies, MAHs have channelled 
communications between registry holders and regulators. However the EMA is now 
recommending that they liaise more directly with disease registry holders at an early stage in 
the development of study protocols.  This is intended to improve clarity on what information 
is needed and what is available. The UKCFR endorses early engagement to avoid 
unrealistic expectations and to facilitate early implementation for any addition registry data 
fields that may be required. Improved communication should significantly shorten the current 
12-18 months timeline for agreeing study protocols, speeding up study completion and 
reporting.  
 
The recent Life Sciences Industrial Strategy (9) urges the development of more national 
patient registries, particularly in rare or orphan diseases, actively supported by patient 
charities. The UK government has agreed to the implementation of the UK Strategy for Rare 
Disease (10) which calls for better use of rare disease registries in research and 
development. The UKCFR has developed a successful model for partnership with industry to 
conduct long term safety and efficacy studies, aimed at improving the safety of medicines 
and the quality of pharmacovigilance.  It is hoped that this ground-breaking experience will 
prove of value to organisations holding registries or developing new ones in response to 
these strategies, and will be of interest to pharmaceutical companies and trade associations, 
in advancing the quality of real world studies, to the benefit of patients.       
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